Gotowe bibliografie tematyczne / Vascular endothelial growth factor

Gotowa bibliografia na temat „Vascular endothelial growth factor”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 20 lutego 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Spis treści

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Vascular endothelial growth factor”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Vascular endothelial growth factor"

1

Ferrara, Napoleone. "Vascular Endothelial Growth Factor". Arteriosclerosis, Thrombosis, and Vascular Biology 29, nr 6 (czerwiec 2009): 789–91. http://dx.doi.org/10.1161/atvbaha.108.179663.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Wirostko, Barbara M. "Vascular Endothelial Growth Factor". Ophthalmology 114, nr 10 (październik 2007): 1954–55. http://dx.doi.org/10.1016/j.ophtha.2007.05.018.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Ferrara, N. "Vascular endothelial growth factor". European Journal of Cancer 32, nr 14 (grudzień 1996): 2413–22. http://dx.doi.org/10.1016/s0959-8049(96)00387-5.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Zachary, Ian. "Vascular endothelial growth factor". International Journal of Biochemistry & Cell Biology 30, nr 11 (listopad 1998): 1169–74. http://dx.doi.org/10.1016/s1357-2725(98)00082-x.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Clauss, Matthias, i Wolfgang Schaper. "Vascular Endothelial Growth Factor". Circulation Research 86, nr 3 (18.02.2000): 251–52. http://dx.doi.org/10.1161/01.res.86.3.251.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Ferrara, Napoleone. "Vascular endothelial growth factor". Trends in Cardiovascular Medicine 3, nr 6 (listopad 1993): 244–50. http://dx.doi.org/10.1016/1050-1738(93)90046-9.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Yip-Schneider, Michele, i C. Max Schmidt. "Vascular Endothelial Growth Factor". Journal of the American College of Surgeons 219, nr 3 (wrzesień 2014): 591–92. http://dx.doi.org/10.1016/j.jamcollsurg.2014.06.009.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Aziz, Reem A. Abdel. "Serum Vascular Endothelial Growth Factor in Children with Beta Thalassemia Major". Journal of Medical Science And clinical Research 04, nr 12 (28.12.2016): 14955–63. http://dx.doi.org/10.18535/jmscr/v4i12.107.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Rama, K., i D. Kanmani. "Implication of VEGF (Vascular Endothelial Growth Factor) in Epithelial Ovarian Neoplasms". Indian Journal of Pathology: Research and Practice 5, nr 3 (2016): 283–90. http://dx.doi.org/10.21088/ijprp.2278.148x.5316.8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Arkonac, Burak M., Lauren C. Foster, Nicholas E. S. Sibinga, Cam Patterson, Kaihua Lai, Jer-Chia Tsai, Mu-En Lee, Mark A. Perrella i Edgar Haber. "Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells." Journal of Biological Chemistry 273, nr 15 (kwiecień 1998): 9352. http://dx.doi.org/10.1016/s0021-9258(18)49640-8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Vascular endothelial growth factor"

1

Krishnan, Jaya. "The role of vascular endothelial growth factor receptor 3, and its ligands vascular endothelial growth factor C and vascular endothelial growth factor D in tumour metastasis and haematopoeisis". Thesis, University of London, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.270576.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Prahst, Claudia. "Neuropilin-vascular endothelial growth factor signaling in endothelial cells". [S.l. : s.n.], 2007. http://nbn-resolving.de/urn:nbn:de:bsz:25-opus-51230.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Botelho, Francisco José dos Santos. "Vascular endothelial growth factor and prostate cancer". Master's thesis, Faculdade de Medicina da Universidade do Porto, 2009. http://hdl.handle.net/10216/22291.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Botelho, Francisco José dos Santos. "Vascular endothelial growth factor and prostate cancer". Dissertação, Faculdade de Medicina da Universidade do Porto, 2009. http://hdl.handle.net/10216/22291.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Jacobsen, Jan. "Vascular endothelial growth factor in renal cell carcinoma". Doctoral thesis, Umeå : Kirurgisk och perioperativ vetenskap, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-713.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Wang, Wenying. "Angiogenesis mediated by vascular endothelial growth factor (VEGF)". Thesis, University of Bristol, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.419061.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Roberts, Selene Karen. "Signalling via vascular endothelial growth factor receptor complexes". Thesis, University of Leicester, 2005. http://hdl.handle.net/2381/29705.

Pełny tekst źródła
Streszczenie:
This study sought to investigate the role of various components of VEGF receptor signalling complexes using fluorescence microscopy to complement conventional biochemical techniques. Using DsRedII-Grp1 to visualise the product of the reaction catalysed by PI3K, activation of PI3K downstream of VEGF receptor-2 is shown. There was no obvious relocalisation of p85 to phosphorylated receptors however a small amount of GFP-p85 associates with, and is phosphorylated in response to, activated VEGF receptor-2. The Shc-related adaptor ShcB/Sck was localised to the plasma membrane in stimulated endothelial cells and associated with activated VEGF receptor-2. PTB and SH2 protein domains, contained within Sck, facilitated these events. Key tyrosine amino acids found within Grb2 binding motifs of ShcA and Sck were phosphorylated in response to VEGF. Tyrosine residues 315 and 316 of Sck were phosphorylated to a greater extent when compared to the corresponding residues of ShcA. Cells expressing Sck proteins lacking tyrosine phosphorylation sites showed a reduced amount of phospho-ERK and DNA synthesis. VEGF receptor-2 was internalised and degraded in response to VEGF. This occurred, at least in part, through the conventional endocytic pathway. VEGF receptor-2 is localised in caveolin-1 and EEA-1 containing vesicles, which is suggestive of internalisation via caveolae and/or early endosomes. Nedd4 co-localises with VEGF receptor-1 at regions of the plasma membrane and this association was confirmed by co-immunoprecipitation. The over-expression of Nedd4 enhanced the degradation of VEGF receptor-1.
Style APA, Harvard, Vancouver, ISO itp.
8

Aase, Karin. "On vascular endothelial growth factor B and platelet-derived growth factor C : two members of the VEGF/PDGF family of growth factors /". Stockholm : Karolinska Univ. Press, 2001. http://diss.kib.ki.se/2001/91-89428-14-5/.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Ng, Hoi-man, i 伍凱敏. "Regulation of vascular endothelial growth factor by ginsenoside RG1 inhuman endothelial cells". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B43955915.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Fearnley, Gareth William. "Vascular endothelial growth factor A isoform-specific regulation of endothelial cell function". Thesis, University of Leeds, 2015. http://etheses.whiterose.ac.uk/10721/.

Pełny tekst źródła
Streszczenie:
Vascular endothelial growth factor A (VEGF-A) binding to the receptor tyrosine kinase (RTK) vascular endothelial growth factor 2 (VEGFR2) triggers an array of downstream signal transduction pathways which modulate a multitude of endothelial cell responses, such as cell migration, proliferation, tubulogenesis and cell-cell interactions. Multiple splice isoforms of VEGF-A exist, yet it is unclear how different VEGF-A isoforms bind to the same RTK to program distinct cellular responses. The work presented in this PhD thesis evaluated VEGF-A isoforms for their ability to program VEGFR2 endocytosis, post-translational modification, proteolysis and terminal degradation. Such changes in VEGFR2 status were linked to downstream signal transduction and gene expression, with relevance to cell function and vascular physiology. VEGF-A isoforms differentially promoted VEGFR2 tyrosine transautophosphorylation and endocytosis. Different VEGFR2-VEGF-A complexes exhibit altered ubiquitination, a hallmark of trafficking through the endosome-lysosome system for subsequent terminal degradation and proteolysis. VEGF-A isoform-specific VEGFR2 phosphorylation coupled with endocytosis and delivery to early endosomes is required for isoform-specific activation of the MEK1-ERK1/2 signal transduction pathway and endothelial cell proliferation. VEGF-A isoforms also exhibited differences in their ability to stimulate arterial regeneration in a mouse hind limb ischaemia model. VEGF-A isoform-specific ERK1/2 activation was essential for the phosphorylation of activating transcription factor 2 (ATF-2) at residue T71. Differential activation of ATF-2 regulated VEGF-A isoform-specific gene transcription (e.g. VCAM-1) and endothelial cell responses, such as leukocyte recruitment. Additionally, basal ATF-2-pT71 levels are required to maintain endothelial cell cycle commitment, via repressing p53-dependent gene transcription. Furthermore, VEGF-A isoforms promoted differential PLC1 phosphorylation and a subsequent isoform-specific increase in cytosolic calcium ions. A functional consequence of this VEGF-A isoform-specific calcium ion flux, was differential dephosphorylation and subsequent nuclear translocation of the transcription factor NFATc2 (NFAT1) in order to regulate endothelial cell migration. Thus, this study provides a mechanistic framework for understanding how different ligand isoforms differentially program RTK functionality in health and disease.
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Vascular endothelial growth factor"

1

Woods, Stacy Ann. Signalling pathways regulating expression of vascular endothelial growth factor in human malignant astrocytomas. Ottawa: National Library of Canada, 2001.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Perlmutter, Robin Alexandra. Differential effects of platelet-derived growth factor isoforms on large and small vessel endothelial cells and vascular smooth muscle cells. [s.l: s.n.], 1992.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Liu, Bo. A study of the biological functions of vascular endothelial growth factor in tumour development. Birmingham: University of Birmingham, 1997.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Dunk, Caroline Elizabeth. The role of the vascular endothelial growth factor family in trophoblast and endothelial cell function: Relating to placental development. Birmingham: University of Birmingham, 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

International Workshop "Novel Angiogenic Mechanisms" (2002 Columbus, Ohio). Novel angiogenic mechanisms: Role of circulating progenitor endothelial cells. New York: Kluwer Academic/Plenum, 2003.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

I, Moldovan Nicanor, red. Novel angiogenic mechanisms: Role of circulating progenitor endothelial cells. New York: Kluwer Academic/Plenum, 2003.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Bayko, Liisa Ann. The contribution of vascular endothelial growth factor induced angiogenesis to the progression of primary human melanoma. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

service), ScienceDirect (Online, red. Tissue-specific vascular endothelial signals and vector targeting. Amsterdam: Elsevier, 2009.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Sisi, Paraskevi. Investigation of the role of vascular endothelial growth factor in the process of cervical ripening during parturition. Birmingham: University of Birmingham, 1997.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Fuchs, Johanna. Photodynamische - und anti - VEGF-Therapie als Kombinationstherapie bei der exsudativen altersabhängigen Makuladegeneration. Regensburg: Universitätsbibliothek Regensburg, 2017.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Części książek na temat "Vascular endothelial growth factor"

1

Marti, Hugo H. "Vascular Endothelial Growth Factor". W Advances in Experimental Medicine and Biology, 375–94. Boston, MA: Springer US, 2003. http://dx.doi.org/10.1007/978-1-4615-0123-7_14.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Marmé, Dieter. "Vascular Endothelial Growth Factor". W Encyclopedia of Cancer, 1–3. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_6155-2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Marmé, Dieter. "Vascular Endothelial Growth Factor". W Encyclopedia of Cancer, 4788–90. Berlin, Heidelberg: Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-46875-3_6155.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Shibuya, Masabumi. "Vascular Permeability/Vascular Endothelial Growth Factor". W Angiogenesis, 89–98. Boston, MA: Springer US, 2008. http://dx.doi.org/10.1007/978-0-387-71518-6_8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Liang, Michelle C., i Jeffrey S. Heier. "Anti-vascular Endothelial Growth Factor". W Encyclopedia of Ophthalmology, 1–8. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-35951-4_1091-1.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Erdmann, Alexandra, i Erin S. Costanzo. "Vascular Endothelial Growth Factor (VEGF)". W Encyclopedia of Behavioral Medicine, 2304–5. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-39903-0_619.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Turner, J. Rick, J. Rick Turner, Jonathan Newman, Alexandra Erdmann, Erin Costanzo, Leah Rosenberg, Jonathan Newman i in. "Vascular Endothelial Growth Factor (VEGF)". W Encyclopedia of Behavioral Medicine, 2028–29. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1005-9_619.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Salajegheh, Ali. "Vascular Endothelial Growth Factor (VEGF)". W Angiogenesis in Health, Disease and Malignancy, 363–74. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-28140-7_58.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Stewart, Michael W. "Targeting Vascular Endothelial Growth Factor". W Diabetic Retinopathy, 99–139. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-3509-8_4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Sarmiento, Roberta, Roberta Franceschini, Sabrina Meo, Massimo Gion, Raffele Longo i Giampietro Gasparini. "Circulating Vascular Endothelial Growth Factor". W Biomarkers in Breast Cancer, 267–92. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1385/1-59259-915-x:267.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Vascular endothelial growth factor"

1

Lee, Seung Hyeun, Eun Joo Lee, Gyu Young Hur, Sung Yong Lee, Sang Yeub Lee, Je Hyeong Kim, Chol Shin i in. "Expression Of Vascular Endothelial Growth Factor (VEGF) And Vascular Endothelial Growth Factor Receptors (VEGFRs) In Lung Tissue Of Smokers And COPD Patients". W American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a2999.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Mitsunaga, Makoto, Takashi Nishimura i Kimihiro Ito. "Abstract 5767: Vascular endothelial growth factor receptor 2 targeted photoimmunotherapy". W Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5767.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Rebrov, B., E. Komarova, A. Blagodarenko, G. Belkina i I. Pokryshka. "AB0196 Vascular endothelial growth factor in patients with rheumatoid arthritis". W Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.2373.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Chetty, Anne, Gong-Jie Cao i Heber C. Nielsen. "Vascular Remodeling In Asthma: Mechanism Of Expression Of Vascular Endothelial Growth Factor (VEGF)". W American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a2132.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Colfer, Elaine, Christine M. Costello, Sandro De Falco, Paul McLoughlin i Katherine Howell. "Placental Growth Factor Inactivation Impairs Vascular Endothelial Growth Factor Regulation In The Hypoxic Mouse Lung". W American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a6499.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Sevostyanova, V. V., Y. I. Khodyrevskaya, T. V. Glushkova, L. V. Antonova, Y. A. Kudryavtseva, O. L. Barbarash i L. S. Barbarash. "Preparation and features of polycaprolactone vascular grafts with the incorporated vascular endothelial growth factor". W ADVANCED MATERIALS WITH HIERARCHICAL STRUCTURE FOR NEW TECHNOLOGIES AND RELIABLE STRUCTURES. AIP Publishing LLC, 2015. http://dx.doi.org/10.1063/1.4932895.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Walters, Matthew S., Giacomo Curradi, Bi-Sen Ding, Shahin Rafii, Neil R. Hackett i Ronald G. Crystal. "Vascular Endothelial Growth Factor-Mediated Cross-Talk Regulates Endothelial Cell-Dependent Growth Support Of Human Airway Basal Cells". W American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a3906.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Hajighasemi, Fatemeh, i Abbas Mirshafiey. "Effect of verapamil on vascular endothelial growth factor production in immunocompetent cells". W Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa4011.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Fedorczyk, Bartlomiej, Dagmara Tymecka, Karolina Grabowska, Anna Puszko, Piotr Lipinski, Gerard Y. Perret i Aleksandra Misicka. "Inhibitors of the Neuropilin-1 and Vascular Endothelial Growth Factor 165 Interaction". W 35th European Peptide Symposium. Prompt Scientific Publishing, 2018. http://dx.doi.org/10.17952/35eps.2018.204.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Morss, Alisa, Michael Jonas i Elazer R. Edelman. "Elevated Basement Membrane Fibroblast Growth Factor-2 Protects Endothelial Cells in High Glucose". W ASME 2007 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2007. http://dx.doi.org/10.1115/sbc2007-176187.

Pełny tekst źródła
Streszczenie:
Vascular disease is the primary cause of morbidity and mortality in diabetics. Diabetic vascular disease is disseminated and includes renal capillary hypertrophy, reduced wound repair, impaired angiogenesis, and rapid and excessive hyperplasia after endovascular intervention [1, 2]. No single biochemical aberration unifies the diffuse nature of diabetic vascular disease. Hyperglycemia has been implicated, and yet glucose effects persist long after restoration of euglycemia. It is possible that acute fluctuations in glucose concentration have prolonged cell and tissue effects.
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Vascular endothelial growth factor"

1

Palade, George E. Vascular Endothelial Growth Factor and Receptors in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, kwiecień 1999. http://dx.doi.org/10.21236/ada378724.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Avraham, Hava. Studies of Vascular Endothelial Growth Factor (VEGF) Signaling in Breast Cancer Cells. Fort Belvoir, VA: Defense Technical Information Center, lipiec 2001. http://dx.doi.org/10.21236/ada395916.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Avraham, Hava. Studies of Vascular Endothelial Growth Factor (VEGF) Signaling in Breast Cancer Cells. Fort Belvoir, VA: Defense Technical Information Center, lipiec 2002. http://dx.doi.org/10.21236/ada412712.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Liu, Kun, Jing Wu, Xiaoning He, Jia Liu i Fang Qi. Anti-Vascular Endothelial Growth Factor (anti-VEGF) for Diabetic Macular Edema (DME): A Systematic Review and Network Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, czerwiec 2021. http://dx.doi.org/10.37766/inplasy2021.6.0009.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Chen, Qiu. Retinal blood oxygen saturation and Vascular Endothelial Growth Factor-A in early diabetic retinopathy：a protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review Protocols, kwiecień 2020. http://dx.doi.org/10.37766/inplasy2020.4.0161.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Tan, Linlin, Zhijie Wang, Yuchun Ni, Fupeng Zhang, Zhaowei Huang, Zhipeng Zhang, Jiaqi Yan i Mei Wu. The efficacy and safety of vascular endothelial growth factor receptor (VEGFR ) inhibitors for recurrent ovarian cancer: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, luty 2021. http://dx.doi.org/10.37766/inplasy2021.2.0019.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Zhang, Yun, Zhaolun Cai, Xueting Liu, Tiancong Chang, Xun Li, You Tang, Bo Zhang i Meixia Zhang. Comparative efficacy and safety of anti-vascular endothelial growth factor monotherapies for neovascular age-related macular degeneration: a systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, lipiec 2020. http://dx.doi.org/10.37766/inplasy2020.7.0007.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Liu, Zhigao, Shuya Wang, Aihua Ma i Bojun Zhao. Comparative efficacy and safety of Anti-Vascular Endothelial Growth Factors for Central Retinal Vein Occlusion A protocol for systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, listopad 2021. http://dx.doi.org/10.37766/inplasy2021.11.0073.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Li, Ting, Shudan Ge, Wei Zheng, Chao Luan, Xingtong Liu, Zongxiu Luo, Qi Zhao i Lulu Xie. Effectiveness and safety of panretinal photocoagulation combined with intravitreous ranibizumab for patients with type 2 proliferative diabetic retinopathy：A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, kwiecień 2022. http://dx.doi.org/10.37766/inplasy2022.4.0048.

Pełny tekst źródła
Streszczenie:
Review question / Objective: Our study aims to synthesise results from randomised controlled trials to assess the effectiveness and safety of PRP combined with intravitreous ranibizumab for T2PDR. Condition being studied: Diabetic retinopathy (DR) is the most common complication of diabetes mellitus, which will seriously affect the quality of life of patients and bring great burden to patients’ families and society. DR is one of the most important diseases of blindness in people aged 20 to 60 years worldwide. Nearly 15% of diabetic patients with a disease duration of more than 5 years were combined with DR.The prevalence of vision threatening diabetic retinopathy in the United States is 4.4 percent. Worldwide, the prevalence is estimated at 10.2%.At present, the treatment methods for type 2 proliferative diabetic retinopathy (T2PDR), at home and abroad mainly include retinal laser photocoagulation and intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors.
Style APA, Harvard, Vancouver, ISO itp.
10

Zhao, Tongtao, Hao Wang, Peng Gu i Xi Yu. Prognostic factors associated with the outcome of anti-vascular epithelium growth factor treatment in patients with myopic choroidal neovascularization：a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, kwiecień 2022. http://dx.doi.org/10.37766/inplasy2022.4.0047.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Vascular endothelial growth factor” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii